A Year After IPO, Entelos Targets Drug Repositioning, Oncology PhysioLab in '07 | GenomeWeb
Entelos celebrated its one-year anniversary as a publicly traded company this month, and laid out a series of goals that it plans to meet during 2007. Among these is a new focus on the use of its PhysioLab biosimulation platform for drug repositioning and the development of a new PhysioLab platform that will focus on oncology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.